The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders

Clozapine can cause severe adverse effects yet it is associated with reduced mortality risk. We test the hypothesis this association is due to increased clinical monitoring and investigate risk of premature mortality from natural causes. We identified 14 754 individuals (879 deaths) with serious mental illness (SMI) including schizophrenia, schizoaffective and bipolar disorders aged ≥ 15 years in a large specialist mental healthcare case register linked to national mortality tracing. In this cohort study we modeled the effect of clozapine on mortality over a 5-year period (2007–2011) using Cox regression. Individuals prescribed clozapine had more severe psychopathology and poorer functional status. Many of the exposures associated with clozapine use were themselves risk factors for increased mortality. However, we identified a strong association between being prescribed clozapine and lower mortality which persisted after controlling for a broad range of potential confounders including clinical monitoring and markers of disease severity (adjusted hazard ratio 0.4; 95% CI 0.2–0.7; p = .001). This association remained after restricting the sample to those with a diagnosis of schizophrenia or those taking antipsychotics and after using propensity scores to reduce the impact of confounding by indication. Among individuals with SMI, those prescribed clozapine had a reduced risk of mortality due to both natural and unnatural causes. We found no evidence to indicate that lower mortality associated with clozapine in SMI was due to increased clinical monitoring or confounding factors. This is the first study to report an association between clozapine and reduced risk of mortality from natural causes.

[1]  K. Rothman,et al.  Mortality in current and former users of clozapine , 1996, Schizophrenia Research.

[2]  M. Hotopf,et al.  Functional Status and All-Cause Mortality in Serious Mental Illness , 2012, PloS one.

[3]  H. Meltzer.  Clozapine: balancing safety with superior antipsychotic efficacy. , 2012, Clinical schizophrenia & related psychoses.

[4]  J. Suvisaari,et al.  Antipsychotics and mortality in first-onset schizophrenia: Prospective Finnish register study with 5-year follow-up , 2013, Schizophrenia Research.

[5]  R. Baldessarini,et al.  Suicidal risk during treatment with clozapine: a meta-analysis , 2005, Schizophrenia Research.

[6]  J. Norrie,et al.  Using patient-reported outcomes in schizophrenia: the Scottish Schizophrenia Outcomes Study. , 2009, Psychiatric services.

[7]  Matthew Broadbent,et al.  Associations between symptoms and all-cause mortality in individuals with serious mental illness. , 2012, Journal of psychosomatic research.

[8]  A. Andrews,et al.  Maggots are useful in treating infected or necrotic wounds , 1999, BMJ.

[9]  Richard Gray,et al.  Serious mental illness and physical health problems: a discussion paper. , 2007, International journal of nursing studies.

[10]  Andrea C. Fernandes,et al.  All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study , 2010, BMC psychiatry.

[11]  David Taylor,et al.  Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. , 2009, The British journal of psychiatry : the journal of mental science.

[12]  Shitij Kapur,et al.  Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation , 2012, British Journal of Psychiatry.

[13]  J. Wing,et al.  Health of the Nation Outcome Scales (HoNOS) , 1999, British Journal of Psychiatry.

[14]  S. Kumra,et al.  Clozapine and “High-Dose” Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison , 2008, Biological Psychiatry.

[15]  I. Nazareth,et al.  Physical activity, dietary habits and Coronary Heart Disease risk factor knowledge amongst people with severe mental illness , 2007, Social Psychiatry and Psychiatric Epidemiology.

[16]  Andrea C. Fernandes,et al.  LIFE EXPECTANCY AT BIRTH FOR PEOPLE WITH SERIOUS MENTAL ILLNESS FROM A SECONDARY MENTAL HEALTH CARE CASE REGISTER IN LONDON, UK , 2011 .

[17]  R. Conley,et al.  Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. , 2010, The Journal of clinical psychiatry.

[18]  C. Dibben,et al.  The English indices of deprivation 2004 , 2011 .

[19]  J. Newcomer,et al.  The Metabolic Effects of Antipsychotic Medications , 2006, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[20]  J K Wing,et al.  Health of the Nation Outcome Scales (HoNOS) , 1998, British Journal of Psychiatry.

[21]  B. Barraclough,et al.  Excess mortality of mental disorder , 1998, British Journal of Psychiatry.

[22]  C Michael Stein,et al.  Atypical antipsychotic drugs and the risk of sudden cardiac death. , 2009, The New England journal of medicine.

[23]  Andrea C. Fernandes,et al.  Associations between substance use disorder sub-groups, life expectancy and all-cause mortality in a large British specialist mental healthcare service. , 2011, Drug and alcohol dependence.

[24]  Giuseppe Curigliano,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[25]  A. Fagiolini,et al.  The effects of undertreated chronic medical illnesses in patients with severe mental disorders. , 2009, The Journal of clinical psychiatry.

[26]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[27]  Sarity Dodson,et al.  Health and Quality of Life Outcomes , 2005 .

[28]  M. Orrell,et al.  Validity and reliability of the Health of the Nation Outcome Scales in psychiatric patients in the community , 1999, British Journal of Psychiatry.

[29]  E. Guallar,et al.  Guideline-concordant antipsychotic use and mortality in schizophrenia. , 2013, Schizophrenia bulletin.

[30]  Patrick Keown,et al.  Retrospective analysis of hospital episode statistics, involuntary admissions under the Mental Health Act 1983, and number of psychiatric beds in England 1996-2006 , 2008, British medical journal.

[31]  Communities,et al.  English Indices of Deprivation , 2013 .

[32]  S. Stahl,et al.  Which comes first: atypical antipsychotic treatment or cardiometabolic risk? , 2009, Acta psychiatrica Scandinavica.

[33]  Marilyn A Winkleby,et al.  Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. , 2013, The American journal of psychiatry.

[34]  M. Marshall.  Modernising mental health services , 1999, BMJ.

[35]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[36]  R. Kilian,et al.  Health behavior in psychiatric in‐patients compared with a German general population sample , 2006, Acta psychiatrica Scandinavica.

[37]  Antti Tanskanen,et al.  11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) , 2009, The Lancet.

[38]  Graham Thornicroft,et al.  The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data , 2009, BMC psychiatry.

[39]  J. Birtwistle,et al.  The unhealthy lifestyle of people with schizophrenia , 1999, Psychological Medicine.

[40]  Arcadio Erlicher,et al.  Health of the Nation Outcome Scales (HoNOS) , 2013 .

[41]  M. Goldacre,et al.  Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006 , 2011, BMJ : British Medical Journal.

[42]  C. Correll,et al.  Real‐world effectiveness of clozapine in patients with bipolar disorder: results from a 2‐year mirror‐image study , 2012, Bipolar disorders.

[43]  C. Lançon,et al.  Mortality in schizophrenia , 2006, Pharmacoepidemiology and drug safety.